APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human cytomegalovirus 65 kDa Phosphoprotein

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Human cytomegalovirus 65 kDa Phosphoprotein Industry Growth and Trends Forecast to 2032

19 December 202592 pages

Choose your research edition.

Industry ResearchHuman cytomegalovirus 65 kDa Phosphoprotein Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Human cytomegalovirus 65 kDa Phosphoprotein Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Human cytomegalovirus 65 kDa Phosphoprotein Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human cytomegalovirus 65 kDa Phosphoprotein Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Human cytomegalovirus 65 kDa Phosphoprotein Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Human cytomegalovirus 65 kDa Phosphoprotein market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Human cytomegalovirus 65 kDa Phosphoprotein is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Human cytomegalovirus 65 kDa Phosphoprotein is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human cytomegalovirus 65 kDa Phosphoprotein is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Human cytomegalovirus 65 kDa Phosphoprotein include Astellas Pharma Inc, Hookipa Biotech AG, Immunomic Therapeutics Inc, Vakzine Projekt Management GmbH, Vaximm AG, VBI Vaccines Inc and Vical Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Human cytomegalovirus 65 kDa Phosphoprotein market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Human cytomegalovirus 65 kDa Phosphoprotein market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Human cytomegalovirus 65 kDa Phosphoprotein market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Human cytomegalovirus 65 kDa Phosphoprotein.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Human cytomegalovirus 65 kDa Phosphoprotein market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Human cytomegalovirus 65 kDa Phosphoprotein Market by Company

Astellas Pharma Inc

Hookipa Biotech AG

Immunomic Therapeutics Inc

Vakzine Projekt Management GmbH

Vaximm AG

VBI Vaccines Inc

Vical Inc

Human cytomegalovirus 65 kDa Phosphoprotein Segment by Type

HB-101

ASP-0113

PepVax

CyMVectin

Others

Human cytomegalovirus 65 kDa Phosphoprotein Segment by Application

Hemotaological Tumor

Kidney Transplant Rejection

Brain Tumor

Liver Transplant Rejection

Others

Human cytomegalovirus 65 kDa Phosphoprotein Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human cytomegalovirus 65 kDa Phosphoprotein market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human cytomegalovirus 65 kDa Phosphoprotein and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human cytomegalovirus 65 kDa Phosphoprotein.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Human cytomegalovirus 65 kDa Phosphoprotein manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Human cytomegalovirus 65 kDa Phosphoprotein in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of HB-101 Table 2. Major Company of ASP-0113 Table 3. Major Company of PepVax Table 4. Major Company of CyMVectin Table 5. Major Company of Others Table 6. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2026) & (K Units) Table 8. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Volume by Type (2021-2026) Table 9. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2026) & (US$ Million) Table 10. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Value by Type (2021-2026) Table 11. Global Human cytomegalovirus 65 kDa Phosphoprotein Price by Type (2021-2026) & (US$/Unit) Table 12. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2027-2032) & (K Units) Table 13. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Volume by Type (2027-2032) Table 14. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2027-2032) & (US$ Million) Table 15. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Value by Type (2027-2032) Table 16. Global Human cytomegalovirus 65 kDa Phosphoprotein Price by Type (2027-2032) & (US$/Unit) Table 17. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2026) & (K Units) Table 18. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2026) & (K Units) Table 20. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2026) & (K Units) Table 22. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2026) & (K Units) Table 24. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2026) & (K Units) Table 26. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales by Type (2021-2026) & (US$ Million) Table 27. Human cytomegalovirus 65 kDa Phosphoprotein Industry Trends Table 28. Human cytomegalovirus 65 kDa Phosphoprotein Industry Drivers Table 29. Human cytomegalovirus 65 kDa Phosphoprotein Industry Opportunities and Challenges Table 30. Human cytomegalovirus 65 kDa Phosphoprotein Industry Restraints Table 31. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Human cytomegalovirus 65 kDa Phosphoprotein Revenue Market Share by Company (2021-2026) Table 33. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Company (2021-2026) & (K Units) Table 34. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Share by Company (2021-2026) Table 35. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Price by Company (2021-2026) & (US$/Unit) Table 36. Global Human cytomegalovirus 65 kDa Phosphoprotein Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Human cytomegalovirus 65 kDa Phosphoprotein Major Company Production Sites and Headquarters Table 38. Global Human cytomegalovirus 65 kDa Phosphoprotein Company, Product Type & Application Table 39. Global Human cytomegalovirus 65 kDa Phosphoprotein Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Human cytomegalovirus 65 kDa Phosphoprotein by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region (2021-2026) & (K Units) Table 44. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Volume by Region (2021-2026) Table 45. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region (2021-2026) & (US$ Million) Table 46. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Value by Region (2021-2026) Table 47. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 48. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region (2027-2032) & (K Units) Table 49. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Volume by Region (2027-2032) Table 50. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Region (2027-2032) & (US$ Million) Table 51. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Value by Region (2027-2032) Table 52. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 53. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2026) & (K Units) Table 55. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Volume by Application (2021-2026) Table 56. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2026) & (US$ Million) Table 57. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Value by Application (2021-2026) Table 58. Global Human cytomegalovirus 65 kDa Phosphoprotein Price by Application (2021-2026) & (US$/Unit) Table 59. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2027-2032) & (K Units) Table 60. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Volume by Application (2027-2032) Table 61. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2027-2032) & (US$ Million) Table 62. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Value by Application (2027-2032) Table 63. Global Human cytomegalovirus 65 kDa Phosphoprotein Price by Application (2027-2032) & (US$/Unit) Table 64. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2026) & (K Units) Table 65. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2026) & (K Units) Table 67. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2026) & (K Units) Table 69. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2026) & (K Units) Table 71. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2026) & (K Units) Table 73. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales by Application (2021-2026) & (US$ Million) Table 74. Astellas Pharma Inc Company Information Table 75. Astellas Pharma Inc Business Overview Table 76. Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 78. Astellas Pharma Inc Recent Development Table 79. Hookipa Biotech AG Company Information Table 80. Hookipa Biotech AG Business Overview Table 81. Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 83. Hookipa Biotech AG Recent Development Table 84. Immunomic Therapeutics Inc Company Information Table 85. Immunomic Therapeutics Inc Business Overview Table 86. Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 88. Immunomic Therapeutics Inc Recent Development Table 89. Vakzine Projekt Management GmbH Company Information Table 90. Vakzine Projekt Management GmbH Business Overview Table 91. Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 93. Vakzine Projekt Management GmbH Recent Development Table 94. Vaximm AG Company Information Table 95. Vaximm AG Business Overview Table 96. Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 98. Vaximm AG Recent Development Table 99. VBI Vaccines Inc Company Information Table 100. VBI Vaccines Inc Business Overview Table 101. VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 103. VBI Vaccines Inc Recent Development Table 104. Vical Inc Company Information Table 105. Vical Inc Business Overview Table 106. Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio Table 108. Vical Inc Recent Development Table 109. North America Human cytomegalovirus 65 kDa Phosphoprotein Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 110. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2026) & (K Units) Table 111. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Country (2021-2026) Table 112. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Forecast by Country (2027-2032) & (K Units) Table 113. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share Forecast by Country (2027-2032) Table 114. North America Human cytomegalovirus 65 kDa Phosphoprotein Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 115. North America Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country (2021-2026) & (US$ Million) Table 116. North America Human cytomegalovirus 65 kDa Phosphoprotein Market Share by Country (2021-2026) Table 117. North America Human cytomegalovirus 65 kDa Phosphoprotein Market Size Forecast by Country (2027-2032) & (US$ Million) Table 118. North America Human cytomegalovirus 65 kDa Phosphoprotein Market Share Forecast by Country (2027-2032) Table 119. Europe Human cytomegalovirus 65 kDa Phosphoprotein Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 120. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2026) & (K Units) Table 121. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Country (2021-2026) Table 122. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Forecast by Country (2027-2032) & (K Units) Table 123. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share Forecast by Country (2027-2032) Table 124. Europe Human cytomegalovirus 65 kDa Phosphoprotein Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 125. Europe Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country (2021-2026) & (US$ Million) Table 126. Europe Human cytomegalovirus 65 kDa Phosphoprotein Market Share by Country (2021-2026) Table 127. Europe Human cytomegalovirus 65 kDa Phosphoprotein Market Size Forecast by Country (2027-2032) & (US$ Million) Table 128. Europe Human cytomegalovirus 65 kDa Phosphoprotein Market Share Forecast by Country (2027-2032) Table 129. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 130. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2026) & (K Units) Table 131. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Country (2021-2026) Table 132. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales Forecast by Country (2027-2032) & (K Units) Table 133. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share Forecast by Country (2027-2032) Table 134. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 135. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country (2021-2026) & (US$ Million) Table 136. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Market Share by Country (2021-2026) Table 137. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Market Size Forecast by Country (2027-2032) & (US$ Million) Table 138. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Market Share Forecast by Country (2027-2032) Table 139. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 140. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2026) & (K Units) Table 141. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Country (2021-2026) Table 142. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Sales Forecast by Country (2027-2032) & (K Units) Table 143. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share Forecast by Country (2027-2032) Table 144. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 145. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country (2021-2026) & (US$ Million) Table 146. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Market Share by Country (2021-2026) Table 147. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Market Size Forecast by Country (2027-2032) & (US$ Million) Table 148. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Market Share Forecast by Country (2027-2032) Table 149. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 150. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2026) & (K Units) Table 151. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share by Country (2021-2026) Table 152. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales Forecast by Country (2027-2032) & (K Units) Table 153. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share Forecast by Country (2027-2032) Table 154. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 155. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country (2021-2026) & (US$ Million) Table 156. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Market Share by Country (2021-2026) Table 157. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Market Size Forecast by Country (2027-2032) & (US$ Million) Table 158. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Market Share Forecast by Country (2027-2032) Table 159. Key Raw Materials Table 160. Raw Materials Key Suppliers Table 161. Human cytomegalovirus 65 kDa Phosphoprotein Distributors List Table 162. Human cytomegalovirus 65 kDa Phosphoprotein Customers List Table 163. Research Programs/Design for This Report Table 164. Authors List of This Report Table 165. Secondary Sources Table 166. Primary Sources List of Figures Figure 1. Human cytomegalovirus 65 kDa Phosphoprotein Image Figure 2. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size (2021-2032) & (US$ Million) Figure 4. Global Human cytomegalovirus 65 kDa Phosphoprotein Sales (2021-2032) & (K Units) Figure 5. HB-101 Image Figure 6. Global HB-101 Sales YoY Growth (2021-2032) & (K Units) Figure 7. ASP-0113 Image Figure 8. Global ASP-0113 Sales YoY Growth (2021-2032) & (K Units) Figure 9. PepVax Image Figure 10. Global PepVax Sales YoY Growth (2021-2032) & (K Units) Figure 11. CyMVectin Image Figure 12. Global CyMVectin Sales YoY Growth (2021-2032) & (K Units) Figure 13. Others Image Figure 14. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 15. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Share by Type 2025 VS 2032 Figure 17. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Volume by Type in 2025 Figure 18. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Value by Type in 2025 Figure 19. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Volume by Type in 2025 Figure 20. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Value by Type in 2025 Figure 23. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Human cytomegalovirus 65 kDa Phosphoprotein Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Hemotaological Tumor Image Figure 30. Global Hemotaological Tumor Sales YoY Growth (2021-2032) & (K Units) Figure 31. Kidney Transplant Rejection Image Figure 32. Global Kidney Transplant Rejection Sales YoY Growth (2021-2032) & (K Units) Figure 33. Brain Tumor Image Figure 34. Global Brain Tumor Sales YoY Growth (2021-2032) & (K Units) Figure 35. Liver Transplant Rejection Image Figure 36. Global Liver Transplant Rejection Sales YoY Growth (2021-2032) & (K Units) Figure 37. Others Image Figure 38. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 39. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size Overview by Application (2021-2032) & (US$ Million) Figure 40. Global Human cytomegalovirus 65 kDa Phosphoprotein Market Share by Application 2025 VS 2032 Figure 41. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Volume by Application in 2025 Figure 42. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Value by Application in 2025 Figure 43. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Volume by Application in 2025 Figure 44. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Value by Application in 2025 Figure 45. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Volume by Application in 2025 Figure 46. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Value by Application in 2025 Figure 47. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Volume by Application in 2025 Figure 48. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Value by Application in 2025 Figure 49. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Volume by Application in 2025 Figure 50. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales Market Share in Value by Application in 2025 Figure 51. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. North America Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. North America Human cytomegalovirus 65 kDa Phosphoprotein Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Europe Human cytomegalovirus 65 kDa Phosphoprotein Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Latin America Human cytomegalovirus 65 kDa Phosphoprotein Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 68. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 70. Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Market Share by Country: 2021 VS 2025 VS 2032 Figure 71. Human cytomegalovirus 65 kDa Phosphoprotein Value Chain Figure 72. Key Raw Materials Price Figure 73. Manufacturing Cost Structure Figure 74. Human cytomegalovirus 65 kDa Phosphoprotein Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • HB-101
  • ASP-0113
  • PepVax
  • CyMVectin
  • Others
Applications
  • Hemotaological Tumor
  • Kidney Transplant Rejection
  • Brain Tumor
  • Liver Transplant Rejection
  • Others
Companies covered
  • Astellas Pharma Inc
  • Hookipa Biotech AG
  • Immunomic Therapeutics Inc
  • Vakzine Projekt Management GmbH
  • Vaximm AG
  • VBI Vaccines Inc
  • Vical Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Human cytomegalovirus 65 kDa Phosphoprotein Market by Type
  6. 1.3.1 HB-101
  7. 1.3.2 ASP-0113
  8. 1.3.3 PepVax
  9. 1.3.4 CyMVectin
  10. 1.3.5 Others
  11. 1.4 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Type
  12. 1.4.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Human cytomegalovirus 65 kDa Phosphoprotein Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Human cytomegalovirus 65 kDa Phosphoprotein Industry Trends
  2. 2.2 Human cytomegalovirus 65 kDa Phosphoprotein Industry Drivers
  3. 2.3 Human cytomegalovirus 65 kDa Phosphoprotein Industry Opportunities and Challenges
  4. 2.4 Human cytomegalovirus 65 kDa Phosphoprotein Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Human cytomegalovirus 65 kDa Phosphoprotein Revenue (2021-2026)
  2. 3.2 Global Top Players by Human cytomegalovirus 65 kDa Phosphoprotein Sales (2021-2026)
  3. 3.3 Global Top Players by Human cytomegalovirus 65 kDa Phosphoprotein Price (2021-2026)
  4. 3.4 Global Human cytomegalovirus 65 kDa Phosphoprotein Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Human cytomegalovirus 65 kDa Phosphoprotein Major Company Production Sites & Headquarters
  6. 3.6 Global Human cytomegalovirus 65 kDa Phosphoprotein Company, Product Type & Application
  7. 3.7 Global Human cytomegalovirus 65 kDa Phosphoprotein Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Human cytomegalovirus 65 kDa Phosphoprotein Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Human cytomegalovirus 65 kDa Phosphoprotein Tier 1, Tier 2, and Tier 3
4 Human cytomegalovirus 65 kDa Phosphoprotein Regional Status and Outlook
  1. 4.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Historic Market Size by Region
  3. 4.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Forecasted Market Size by Region
  7. 4.3.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Human cytomegalovirus 65 kDa Phosphoprotein by Application
  1. 5.1 Human cytomegalovirus 65 kDa Phosphoprotein Market by Application
  2. 5.1.1 Hemotaological Tumor
  3. 5.1.2 Kidney Transplant Rejection
  4. 5.1.3 Brain Tumor
  5. 5.1.4 Liver Transplant Rejection
  6. 5.1.5 Others
  7. 5.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Application
  8. 5.2.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size Overview by Application (2021-2032)
  9. 5.2.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Historic Market Size Review by Application (2021-2026)
  10. 5.2.3 Global Human cytomegalovirus 65 kDa Phosphoprotein Forecasted Market Size by Application (2027-2032)
  11. 5.3 Key Regions Market Size by Application
  12. 5.3.1 North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Breakdown by Application (2021-2026)
  13. 5.3.2 Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Breakdown by Application (2021-2026)
  14. 5.3.3 Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales Breakdown by Application (2021-2026)
  15. 5.3.4 South America Human cytomegalovirus 65 kDa Phosphoprotein Sales Breakdown by Application (2021-2026)
  16. 5.3.5 Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Astellas Pharma Inc
  2. 6.1.1 Astellas Pharma Inc Company Information
  3. 6.1.2 Astellas Pharma Inc Business Overview
  4. 6.1.3 Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  6. 6.1.5 Astellas Pharma Inc Recent Developments
  7. 6.2 Hookipa Biotech AG
  8. 6.2.1 Hookipa Biotech AG Company Information
  9. 6.2.2 Hookipa Biotech AG Business Overview
  10. 6.2.3 Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  12. 6.2.5 Hookipa Biotech AG Recent Developments
  13. 6.3 Immunomic Therapeutics Inc
  14. 6.3.1 Immunomic Therapeutics Inc Company Information
  15. 6.3.2 Immunomic Therapeutics Inc Business Overview
  16. 6.3.3 Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  18. 6.3.5 Immunomic Therapeutics Inc Recent Developments
  19. 6.4 Vakzine Projekt Management GmbH
  20. 6.4.1 Vakzine Projekt Management GmbH Company Information
  21. 6.4.2 Vakzine Projekt Management GmbH Business Overview
  22. 6.4.3 Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  24. 6.4.5 Vakzine Projekt Management GmbH Recent Developments
  25. 6.5 Vaximm AG
  26. 6.5.1 Vaximm AG Company Information
  27. 6.5.2 Vaximm AG Business Overview
  28. 6.5.3 Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  30. 6.5.5 Vaximm AG Recent Developments
  31. 6.6 VBI Vaccines Inc
  32. 6.6.1 VBI Vaccines Inc Company Information
  33. 6.6.2 VBI Vaccines Inc Business Overview
  34. 6.6.3 VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  36. 6.6.5 VBI Vaccines Inc Recent Developments
  37. 6.7 Vical Inc
  38. 6.7.1 Vical Inc Company Information
  39. 6.7.2 Vical Inc Business Overview
  40. 6.7.3 Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Product Portfolio
  42. 6.7.5 Vical Inc Recent Developments
7 North America by Country
  1. 7.1 North America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country
  2. 7.1.1 North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2026)
  4. 7.1.3 North America Human cytomegalovirus 65 kDa Phosphoprotein Sales Forecast by Country (2027-2032)
  5. 7.2 North America Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country
  6. 7.2.1 North America Human cytomegalovirus 65 kDa Phosphoprotein Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country (2021-2026)
  8. 7.2.3 North America Human cytomegalovirus 65 kDa Phosphoprotein Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country
  2. 8.1.1 Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2026)
  4. 8.1.3 Europe Human cytomegalovirus 65 kDa Phosphoprotein Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country
  6. 8.2.1 Europe Human cytomegalovirus 65 kDa Phosphoprotein Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country (2021-2026)
  8. 8.2.3 Europe Human cytomegalovirus 65 kDa Phosphoprotein Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country
  2. 9.1.1 Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country
  6. 9.2.1 Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Human cytomegalovirus 65 kDa Phosphoprotein Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country
  2. 10.1.1 South America Human cytomegalovirus 65 kDa Phosphoprotein Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2026)
  4. 10.1.3 South America Human cytomegalovirus 65 kDa Phosphoprotein Sales Forecast by Country (2027-2032)
  5. 10.2 South America Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country
  6. 10.2.1 South America Human cytomegalovirus 65 kDa Phosphoprotein Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country (2021-2026)
  8. 10.2.3 South America Human cytomegalovirus 65 kDa Phosphoprotein Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country
  2. 11.1.1 Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country
  6. 11.2.1 Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Human cytomegalovirus 65 kDa Phosphoprotein Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Human cytomegalovirus 65 kDa Phosphoprotein Value Chain Analysis
  2. 12.1.1 Human cytomegalovirus 65 kDa Phosphoprotein Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Human cytomegalovirus 65 kDa Phosphoprotein Production Mode & Process
  7. 12.2 Human cytomegalovirus 65 kDa Phosphoprotein Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Human cytomegalovirus 65 kDa Phosphoprotein Distributors
  10. 12.2.3 Human cytomegalovirus 65 kDa Phosphoprotein Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst